Valerie Speirs

List of Publications by Year
in descending order

155	7,173	81743	62479
papers	citations	39 h-index	80 g-index

161	161	161	12480
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Male breast cancer: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 85-93.	1.4	43
2	Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. British Journal of Cancer, 2022, 126, 1125-1139.	2.9	54
3	Obituary â€“ Margaret Wilcox. British Journal of Cancer, 2022, , .	2.9	0
4	A biobank perspective on use of tissue samples donated by trial participants. Lancet Oncology, The, 2022, 23, e205.	5.1	2
5	Labeling of a Mutant Estrogen Receptor with an Affimer in a Breast Cancer Cell Line. Biophysical Journal, 2022, , .	0.2	1
6	Analysis of the Clinical Advancements for BRCA-Related Malignancies Highlights the Lack of Treatment Evidence for BRCA-Positive Male Breast Cancer. Cancers, 2022, 14, 3175.	1.7	6
7	The Cellular and Molecular Pathology Biobanking Sample Quality Improvement Tool: A Guide for Improving the Quality of Tissue Collections for Biomedical Research and Clinical Trials in Cancer. Biopreservation and Biobanking, 2021, 19, 86-90.	0.5	3
8	Quality Considerations When Using Tissue Samples for Biomarker Studies in Cancer Research. Biomarker Insights, 2021, 16, 117727192110095.	1.0	5
9	Biobanking in radiotherapy trials â€" a challenge to the clinical research community. Nature Reviews Clinical Oncology, 2021, 18, 191-192.	12.5	1
10	MicroRNA-495/TGF-Î²2/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology, 2021, 192, 114692.	2.0	12
11	Exploring the influence of rural residence on uptake of organized cancer screening â€“ A systematic review of international literature. Cancer Epidemiology, 2021, 74, 101995.	0.8	9
12	Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations. Journal of Pathology: Clinical Research, 2021, , .	1.3	3
13	Preclinical models of glioblastoma: limitations of current models and the promise of new developments. Expert Reviews in Molecular Medicine, 2021, 23, e20.	1.6	20
14	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343
15	Reflections on the upsurge of virtual cancer conferences during the COVID-19 pandemic. British Journal of Cancer, 2020, 123, 698-699.	2.9	19
16	BPA and risk assessment. Lancet Diabetes and Endocrinology,the, 2020, 8, 269.	5.5	2
17	Incidence of male breast cancer in Scotland over a twenty-five-year period (1992â€“2017). European Journal of Surgical Oncology, 2020, 46, 1546-1550.	0.5	9
18	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2020, , 161-165.	0.0	0

#	Article	IF	Citations
19	Male Breast Cancer. Encyclopedia of Pathology, 2020, , 263-268.	0.0	0
20	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERÎ±-positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.5	4
21	Metastatic-niche labelling reveals parenchymal cells with stem features. Nature, 2019, 572, 603-608.	13.7	139
22	A Review of International Biobanks and Networks: Success Factors and Key Benchmarksâ€"A 10-Year Retrospective Review. Biopreservation and Biobanking, 2019, 17, 512-519.	0.5	10
23	Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer. Journal of Pathology, 2019, 247, 381-391.	2.1	33
24	Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Instituteâ€™s Cellular Molecular Pathology (CM-Path) initiative. Journal of Clinical Pathology, 2019, 72, 52-57.	1.0	2
25	Current and Emerging 3D Models to Study Breast Cancer. Advances in Experimental Medicine and Biology, 2019, 1152, 413-427.	0.8	20
26	Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. European Journal of Surgical Oncology, 2018, 44, 429-435.	0.5	62
27	Rho GTPase signaling and role of the Rac1 exchange factor DOCK4 in GBM invasion and vascular growth. Neuro-Oncology, 2018, 20, i17-i17.	0.6	1
28	Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities. Pathobiology, 2018, 85, 220-226.	1.9	21
29	Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. Journal of Pathology: Clinical Research, 2018, 4, 241-249.	1.3	12
30	Characterising the adipose-inflammatory microenvironment in male breast cancer. Endocrine-Related Cancer, 2018, 25, 773-781.	1.6	6
31	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2018, , 1-5.	0.0	0
32	Male Breast Cancer. Encyclopedia of Pathology, 2018, , 1-6.	0.0	0
33	In vivomodels in breast cancer research: progress, challenges and future directions. DMM Disease Models and Mechanisms, 2017, 10, 359-371.	1.2	131
34	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 2017, 7, 45293.	1.6	50
35	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	2.0	9
36	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16

#	Article	IF	Citations
37	CIP2A expression predicts recurrences of tamoxifen-treated breast cancer. Tumor Biology, 2017, 39, 101042831772206.	0.8	2
38	Oestrogen receptor Î² (ERÎ²) regulates osteogenic differentiation of human dental pulp cells. Journal of Steroid Biochemistry and Molecular Biology, 2017, 174, 296-302.	1.2	12
39	Attitudes of female staff and students from two United Kingdom Medical Schools towards donating normal healthy breast tissue and blood samples for biomedical research. Breast Cancer Research and Treatment, 2017, 166, 651-652.	1.1	0
40	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	1.6	14
41	Advances in the development of improved animal-free models for use in breast cancer biomedical research. Biophysical Reviews, 2017, 9, 321-327.	1.5	6
42	Loss of CSMD1 expression disrupts mammary duct formation while enhancing proliferation, migration and invasion. Oncology Reports, 2017, 38, 283-292.	1.2	19
43	The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research. PLoS Biology, 2017, 15, e2000719.	2.6	18
44	SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Research and Treatment, 2016, 156, 447-452.	1.1	11
45	SEARCHBreast: An online resource designed to increase the efficiency of using materials derived from breast cancer studies in animals. Journal of Pathology, 2016, 240, 120-120.	2.1	0
46	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	1.6	6
47	SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers. Breast Cancer Research, 2016, 18, 59.	2.2	2
48	Introducing SEARCHBreast: a virtual resource to facilitate sharing of surplus animal material developed for breast cancer research. Npj Breast Cancer, 2016, 2, 16020.	2.3	1
49	Management of breast cancer in an Asian man with post-traumatic stress disorder: a case report. Journal of Medical Case Reports, 2016, 10, 77.	0.4	0
50	Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nature Communications, 2016, 7, 10305.	5.8	127
51	CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment. Journal of the National Cancer Institute, 2016, 108, .	3.0	75
52	Treatment and outcomes from a large, prospective, national longitudinal cohort study of screen detected ductal carcinoma in situ (DCIS).. Journal of Clinical Oncology, 2016, 34, 1570-1570.	0.8	1
53	An Evaluation of Matrix-Containing and Humanised Matrix-Free 3-Dimensional Cell Culture Systems for Studying Breast Cancer. PLoS ONE, 2016, 11, e0157004.	1.1	14
54	Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancerin vitro. Oncotarget, 2016, 7, 32129-32143.	0.8	19

#	Article	IF	Citations
55	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	0.8	35
56	The SEARCHBreast Portal: A Virtual Bioresource to Facilitate the Sharing of Surplus Animal Materials Derived from Breast Cancer Studies. Open Journal of Bioresources, 2016, 3, .	1.5	0
57	3-D Tissue Modelling and Virtual Pathology as New Approaches to Study Ductal Carcinoma In Situ. ATLA Alternatives To Laboratory Animals, 2015, 43, 377-383.	0.7	6
58	SEARCHBreast Workshop Proceedings: 3D Modelling of Breast Cancer. ATLA Alternatives To Laboratory Animals, 2015, 43, 367-375.	0.7	7
59	Development and characterisation of a 3D multi-cellularin vitromodel of normal human breast: a tool for cancer initiation studies. Oncotarget, 2015, 6, 13731-13741.	0.8	26
60	Share surplus animal tissue. Nature, 2015, 522, 156-156.	13.7	9
61	Lack of CD151/integrin Î±3Î²1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers. British Journal of Cancer, 2015, 113, 1350-1357.	2.9	19
62	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of Hematology and Oncology, 2015, 8, 53.	6.9	32
63	A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis. Nature Communications, 2015, 6, 7286.	5.8	66
64	The Molecular Pathology of Male Breast Cancer. Molecular Pathology Library, 2015, , 309-315.	0.1	0
65	Threeâ€dimensional reconstruction of ductal carcinoma inÂsitu with virtual slides. Histopathology, 2015, 66, 966-973.	1.6	28
66	Obesity and male breast cancer: provocative parallels?. BMC Medicine, 2015, 13, 134.	2.3	26
67	Modelling the Molecular Pathology of Breast Cancer Initiation. Molecular Pathology Library, 2015, , 39-50.	0.1	1
68	Androgen receptor and antiandrogen therapy in male breast cancer. Cancer Letters, 2015, 368, 20-25.	3.2	17
69	Adding value to rare tissue samples donated to biobanks: characterisation of breast tissue and primary cell cultures obtained from a female-to-male transgender patient. Cell and Tissue Banking, 2015, 16, 27-34.	0.5	8
70	A Global View of Breast Tissue Banking. Advances in Experimental Medicine and Biology, 2015, 864, 69-77.	0.8	3
71	Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis. PLoS ONE, 2015, 10, e0139698.	1.1	21
72	Abstract P1-12-12: The insulin like growth factor axis and development of tamoxifen resistance in breast cancer. , 2015, , .		0

#	Article	IF	Citations
73	PSMD9 expression predicts radiotherapy response in breast cancer. Molecular Cancer, 2014, 13, 73.	7.9	18
74	The value of archival tissue blocks in understanding breast cancer biology. Journal of Clinical Pathology, 2014, 67, 272-275.	1.0	11
75	Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Research and Treatment, 2014, 143, 605-607.	1.1	3
76	The potential utility of geminin as a predictive biomarker in breast cancer. Breast Cancer Research and Treatment, 2014, 143, 91-98.	1.1	21
77	External validation of the ImmunoRatio image analysis application for ERÎ± determination in breast cancer. Journal of Clinical Pathology, 2014, 67, 72-75.	1.0	3
78	Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer. Breast Cancer Research and Treatment, 2014, 148, 221-229.	1.1	10
79	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Research and Treatment, 2014, 148, 73-80.	1.1	24
80	Role of miR-26b in carcinoma-associated fibroblasts and effect on migration and invasion of breast cancer epithelial cells. Lancet, The, 2014, 383, S103.	6.3	1
81	A comparative study of the prognostic role of KI67 and geminin in breast cancer. International Journal of Surgery, 2013, 11, 592.	1.1	0
82	Identification of Stage-Specific Breast Markers Using Quantitative Proteomics. Journal of Proteome Research, 2013, 12, 5696-5708.	1.8	23
83	Investment biobankingâ€"increased returns from tissue samples. Nature Reviews Clinical Oncology, 2013, 10, 128-129.	12.5	12
84	Insulin-like growth factor â€" Oestradiol crosstalk and mammary gland tumourigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 345-353.	3.3	46
85	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
86	The practicalities of using tissue slices as preclinical organotypic breast cancer models. Journal of Clinical Pathology, 2013, 66, 253-255.	1.0	52
87	The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of Clinical Pathology, 2013, 66, 169-177.	1.0	43
88	MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion. Journal of Pathology, 2013, 231, 388-399.	2.1	103
89	Estrogen receptor Î²: putting a positive into triple negative breast cancer?. Hormone Molecular Biology and Clinical Investigation, 2013, 16, 117-123.	0.3	7
90	Regulation of estrogen receptor Î²1 expression in breast cancer by epigenetic modification of the 5â€² regulatory region. International Journal of Oncology, 2013, 43, 2039-2045.	1.4	17

#	Article	IF	Citations
91	Pre-Clinical Modeling of Breast Cancer: Which Model to Choose?. , 2013, , 161-175.		0
92	Abstract B127: Loss of miR-92 expression in breast epithelial cells is associated with cancer progression. , 2013, , .		1
93	Perspective: Not just for women. Nature, 2012, 485, S66-S66.	13.7	2
94	Identification of differentially expressed genes in matched formalinâ€fixed paraffinâ€embedded primary and metastatic melanoma tumor pairs. Pigment Cell and Melanoma Research, 2012, 25, 284-286.	1.5	5
95	Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation. Nucleic Acids Research, 2012, 40, e82-e82.	6.5	356
96	CERT depletion predicts chemotherapy benefit and mediates cytotoxic and polyploidâ€specific cancer cell death through autophagy induction. Journal of Pathology, 2012, 226, 482-494.	2.1	48
97	Clinical and functional significance of loss of caveolinâ€1 expression in breast cancerâ€associated fibroblasts. Journal of Pathology, 2012, 227, 490-498.	2.1	87
98	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Research and Treatment, 2012, 133, 949-958.	1.1	119
99	ERÎ²1 Represses FOXM1 Expression through Targeting ERÎ± to Control Cell Proliferation in Breast Cancer. American Journal of Pathology, 2011, 179, 1148-1156.	1.9	31
100	Choosing the right cell line for breast cancer research. Breast Cancer Research, 2011, 13, 215.	2.2	1,153
101	Male breast carcinoma: increased awareness needed. Breast Cancer Research, 2011, 13, 219.	2.2	103
102	Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized Î²-catenin in carcinoma-associated fibroblasts. Histopathology, 2011, 59, 609-618.	1.6	8
103	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Research and Treatment, 2011, 127, 639-648.	1.1	30
104	Towards a-scan imaging via Ultrasonic Vibration Potential measurements. Nuclear Engineering and Design, 2011, 241, 1994-1997.	0.8	4
105	Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma. Hormone Molecular Biology and Clinical Investigation, 2011, 7, 273-8.	0.3	2
106	Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2183-2194.	1.1	141
107	Differential regulation of oestrogen receptor Î² isoforms by 5â€² untranslated regions in cancer. Journal of Cellular and Molecular Medicine, 2010, 14, 2172-2184.	1.6	30
108	Expression of oestrogen receptor Î² isoforms is regulated by transcriptional and post-transcriptional mechanisms. Biochemical Journal, 2010, 429, 283-290.	1.7	32

#	Article	IF	Citations
109	Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2010, 121, 555-563.	1.1	60
110	Estrogen receptor regulation: donâ€™t forget translation. Breast Cancer Research and Treatment, 2010, 121, 251-252.	1.1	2
111	Estrogen Receptor Î²1 Expression Is Regulated by miR-92 in Breast Cancer. Cancer Research, 2010, 70, 4778-4784.	0.4	107
112	Problems (and solutions) in the study of male breast cancer. Rare Tumors, 2010, 2, 78-78.	0.3	8
113	O-9 Loss of CSMD1 expression disrupts cell morphology and mammary duct formation while enhancing proliferation, migration and invasion. European Journal of Cancer, Supplement, 2010, 8, 4.	2.2	0
114	Phosphorylation of Estrogen Receptor Î² at Serine 105 Is Associated with Good Prognosis in Breast Cancer. American Journal of Pathology, 2010, 177, 1079-1086.	1.9	35
115	The rising incidence of male breast cancer. Breast Cancer Research and Treatment, 2009, 115, 429-430.	1.1	130
116	Role of ERÎ² in Clinical Breast Cancer. Cancer Treatment and Research, 2009, 147, 1-20.	0.2	0
117	Conditions of the male breast: Gynaecomastia and male breast cancer (Review). Molecular Medicine Reports, 2009, 3, 21-6.	1.1	10
118	Gene Expression of ERÎ² Isoforms in Laser Microdissected Human Breast Cancers: Implications for Gene Expression Analyses. Analytical Cellular Pathology, 2009, 31, 467-473.	0.7	0
119	Gene expression of ERbeta isoforms in laser microdissected human breast cancers: implications for gene expression analyses. Cellular Oncology, 2009, 31, 467-73.	1.9	4
120	A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Research and Treatment, 2008, 111, 55-63.	1.1	19
121	The evolving role of oestrogen receptor Î² in clinical breast cancer. Breast Cancer Research, 2008, 10, 111.	2.2	15
122	Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. Journal of Clinical Oncology, 2008, 26, 1059-1065.	0.8	409
123	Clinical Importance of Estrogen Receptor Î² Isoforms in Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5825-5825.	0.8	7
124	Nuclear and Cytoplasmic Expression of ERÎ²1, ERÎ²2, and ERÎ²5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients. Clinical Cancer Research, 2008, 14, 5228-5235.	3.2	207
125	Carcinoembryonic Antigen Cell Adhesion Molecule 6 Predicts Breast Cancer Recurrence following Adjuvant Tamoxifen. Clinical Cancer Research, 2008, 14, 405-411.	3.2	44
126	Hormone receptors in defining breast cancer prognosisâ€”time for a rethink?. Nature Clinical Practice Oncology, 2007, 4, 204-205.	4.3	6

#	Article	IF	Citations
127	Estrogen receptor Î²â€"which one and where should we draw the line?. Human Pathology, 2006, 37, 498-498.	1.1	1
128	Pattern of expression of genes linked to epigenetic silencing in human breast cancerâ˜†. Human Pathology, 2006, 37, 989-999.	1.1	41
129	Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cellsin vitro. International Journal of Cancer, 2006, 119, 515-521.	2.3	43
130	A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERÎ² in Archival Formalin-ï¬xed Paraffin Embedded Human Breast Tissue. Breast Cancer Research and Treatment, 2005, 92, 287-293.	1.1	45
131	The Estrogen Receptors Î±, Î², and Î²cx. Clinical Cancer Research, 2005, 11, 8222-8223.	3.2	4
132	A NOVEL CELL ARRAY TECHNIQUE FOR HIGH-THROUGHPUT, CELL-BASED ANALYSIS. In Vitro Cellular and Developmental Biology - Animal, 2005, 41, 185.	0.7	31
133	Variability In Plasma VEGF. Medicine and Science in Sports and Exercise, 2005, 37, S156.	0.2	0
134	Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Research, 2004, 6, 119-27.	2.2	175
135	Oestrogen receptor Î²: what it means for patients with breast cancer. Lancet Oncology, The, 2004, 5, 174-181.	5.1	116
136	Reduced expression of oestrogen receptor ? in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model. Journal of Pathology, 2003, 201, 213-220.	2.1	186
137	Introducing Viewpoints â€" Breast Cancer Research'snew style literature appraisal service. Breast Cancer Research, 2003, 5, 1.	2.2	0
138	Breast cancer cell lines: friend or foe?. Breast Cancer Research, 2003, 5, 89-95.	2.2	238
139	Wnt signalling in mammary carcinogenesis. Breast Cancer Research, 2002, 4, 1.	2.2	3
140	Intracellular Flow Cytometric Analysis of Primary Cultured Breast Tumor Cells. Cancer Investigation, 2002, 20, 340-347.	0.6	6
141	Oestrogen receptor ? in breast cancer: good, bad or still too early to tell?. Journal of Pathology, 2002, 197, 143-147.	2.1	73
142	Evaluation of seven oestrogen receptor ? antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. Journal of Pathology, 2002, 197, 155-162.	2.1	129
143	Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 459-469.	1.2	66
144	Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone. Cancer Genetics and Cytogenetics, 2001, 130, 166-172.	1.0	29

#	Article	IF	Citations
145	Genetic changes in breast cancer detected by comparative genomic hybridisation. , 2000, 86, 494-500.		69
146	Identification of Wild-Type and Exon 5 Deletion Variants of Estrogen Receptor Î² in Normal Human Mammary Gland1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1601-1605.	1.8	49
147	Genetic changes in breast cancer detected by comparative genomic hybridisation. , 2000, 86, 494.		1
148	Activity and gene expression of 17Î²-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. Journal of Steroid Biochemistry and Molecular Biology, 1998, 67, 267-274.	1.2	57
149	Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response ofin vitro cell cultures to steroid hormones. , 1997, 72, 714-719.		36
150	Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: Identification of interleukin-8 as a potential regulatory factor in breast tumours. , 1997, 72, 937-941.		122
151	RT-PCR DETECTION OF CYTOKINE TRANSCRIPTS IN A SERIES OF CULTURED HUMAN MENINGIOMAS. , 1996, 178, 442-446.		12
152	A comparative study of cytokine gene transcripts in normal and malignant breast tissue and primary cell cultures derived from the same tissue samples. , 1996, 66, 551-556.		18
153	Interleukin-3: A putative protective factor against breast cancer which is secreted by male but not female breast fibroblasts. International Journal of Cancer, 1995, 61, 416-419.	2.3	8
154	Cytokine Expression in Normal and Neoplastic Breast Tissue. , 1995, , 101-102.		1
155	Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones. , 0, .		1